Original language | English |
---|---|
Article number | 2102899 |
Journal | European Respiratory Journal |
Volume | 59 |
Issue number | 5 |
DOIs | |
Publication status | Published - 1 May 2022 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: European Respiratory Journal, Vol. 59, No. 5, 2102899, 01.05.2022.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Mortality after admission with pneumonia is higher than after admission with an exacerbation of COPD
AU - The Salford Lung Study Investigators
AU - Vestbo, Jørgen
AU - Waterer, Grant
AU - Leather, David
AU - Crim, Courtney
AU - Bakerly, Nawar Diar
AU - Frith, Lucy
AU - Jacques, Loretta
AU - Harvey, Catherine
AU - Satia, Imran
AU - Woodcock, Ashley
N1 - Funding Information: Support statement: The study was fully funded by GlaxoSmithKline plc. (study number: HZC115151). J. Vestbo, I. Satia and A. Woodcock are supported by the National Institute of Health Research Manchester Biomedical Research Centre (NIHR Manchester BRC). Funding information for this article has been deposited with the Crossref Funder Registry. Funding Information: The Salford Lung Study trial registration number is NCT01551758. Information on GlaxoSmithKline’s data sharing commitments and requesting access to anonymised individual participant data and associated documents can be found at www.clinicalstudydatarequest.com Conflict of interest: J. Vestbo received personal fees from GlaxoSmithKline plc., Chiesi Pharmaceuticals, Boehringer Ingelheim, Novartis and AstraZeneca, congress attendance from Chiesi and holds a grant from Boehringer Ingelheim. G. Waterer received personal fees from GlaxoSmithKline plc. N. Diar Bakerly received grants and personal fees from GlaxoSmithKline plc., Novartis and Almirall/AstraZeneca, and congress attendance from Boehringer Ingelheim. I. Satia received personal fees from GlaxoSmithKline plc., consulting and speaker fees from AstraZeneca and Merck, grants from Merck, GlaxoSmithKline plc, fellowship from ERS Marie-Curie Award, E.J. Moran Campbell Early Career Award, Department of Medicine, McMaster, outside the submitted work. A. Woodcock received speaker fees and expenses from Boehringer Ingelheim, Chiesi, GlaxoSmithKline and Novartis; is chairman/shareholder of Reacta Healthcare and Axalbion, and Chairman of the Medicines Evaluation Unit. D. Leather, L. Frith, L. Jacques and C. Harvey are employees of GlaxoSmithKline plc. and hold shares in the company. C. Crim was an employee of GlaxoSmithKline plc. at the time of the study.
PY - 2022/5/1
Y1 - 2022/5/1
UR - http://www.scopus.com/inward/record.url?scp=85130768108&partnerID=8YFLogxK
U2 - 10.1183/13993003.02899-2021
DO - 10.1183/13993003.02899-2021
M3 - Letter
C2 - 35273031
AN - SCOPUS:85130768108
SN - 0903-1936
VL - 59
JO - European Respiratory Journal
JF - European Respiratory Journal
IS - 5
M1 - 2102899
ER -